메뉴 건너뛰기




Volumn 11, Issue 3, 2010, Pages 149-159

The emerging role of biomarkers in advanced non-small-cell lung cancer

Author keywords

Bevacizumab; Cetuximab; Epidermal growth factor receptor; Erlotinib; FISH; Gefitinib

Indexed keywords

BETA TUBULIN; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; RIBONUCLEOTIDE REDUCTASE; THYMIDYLATE SYNTHASE;

EID: 77952509297     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.019     Document Type: Review
Times cited : (18)

References (90)
  • 1
    • 85031340784 scopus 로고    scopus 로고
    • Non - small-cell lung cancer. NCCN Clinical Practice Guidelines in Oncology. Version 2. 2009. National Comprehensive Cancer Network [Web site]. Accessed: October 28
    • Non - small-cell lung cancer. NCCN Clinical Practice Guidelines in Oncology. Version 2. 2009. National Comprehensive Cancer Network [Web site]. Available at: http://www.nccn.org. Accessed: October 28, 2009.
    • (2009)
  • 2
    • 0037050352 scopus 로고    scopus 로고
    • Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    • Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98
    • (2002) N Engl J Med , vol.346 , pp. 92-98
    • Schiller, J.H.1    Harrington, D.2    Belani, C.P.3
  • 3
    • 62449124416 scopus 로고    scopus 로고
    • Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL
    • Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gem- citabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27:1227-1234
    • (2009) J Clin Oncol , vol.27 , pp. 1227-1234
    • Reck, M.1    Von Pawel, J.2    Zatloukal, P.3
  • 4
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550
    • (2006) N Engl J Med , vol.355 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3
  • 5
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132
    • (2005) N Engl J Med , vol.353 , pp. 123-132
    • Shepherd, F.A.1    Pereira, J.R.2    Ciuleanu, T.3
  • 6
    • 56249109644 scopus 로고    scopus 로고
    • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial
    • Kim E, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372:1809-1818
    • (2008) Lancet , vol.372 , pp. 1809-1818
    • Kim, E.1    Hirsh, V.2    Mok, T.3
  • 9
    • 24944440830 scopus 로고    scopus 로고
    • TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
    • Herbst RS, Prager D, Fehrenbacher L, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892-5899
    • (2005) J Clin Oncol , vol.23 , pp. 5892-5899
    • Herbst, R.S.1    Prager, D.2    Fehrenbacher, L.3
  • 10
    • 34248140107 scopus 로고    scopus 로고
    • Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: The Tarceva Lung Cancer Investigation trial
    • Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the Tarceva Lung Cancer Investigation trial. J Clin Oncol 2007; 25:1545-1552
    • (2007) J Clin Oncol , vol.25 , pp. 1545-1552
    • Gatzemeier, U.1    Pluzanska, A.2    Szczesna, A.3
  • 11
    • 66149192655 scopus 로고    scopus 로고
    • A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)
    • Socinski MA, Saleh MN, Trent DF, et al. A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). Ann Oncol 2009; 20:1068-1073
    • (2009) Ann Oncol , vol.20 , pp. 1068-1073
    • Socinski, M.A.1    Saleh, M.N.2    Trent, D.F.3
  • 12
    • 77952482101 scopus 로고    scopus 로고
    • A phase II study of cetuximab, an IgG1 epidermal growth factor receptor-blocking antibody, in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced non-small cell lung cancer: Final report
    • (abstract 2581)
    • Kim ES, Mauer AM, Tran HT, et al. A phase II study of cetuximab, an IgG1 epidermal growth factor receptor-blocking antibody, in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced non-small cell lung cancer: final report. J Clin Oncol 2005; 22(suppl 18): (abstract 2581).
    • (2005) J Clin Oncol , vol.22 , Issue.SUPPL 18
    • Kim, E.S.1    Mauer, A.M.2    Tran, H.T.3
  • 13
    • 33144481184 scopus 로고    scopus 로고
    • Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small-cell lung cancer
    • Robert F, Blumenschein G, Herbst RS, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:9089-9096
    • (2005) J Clin Oncol , vol.23 , pp. 9089-9096
    • Robert, F.1    Blumenschein, G.2    Herbst, R.S.3
  • 14
    • 33144484457 scopus 로고    scopus 로고
    • Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer
    • Thienelt CD, Bunn PA, Hanna N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005; 23:8786-8793
    • (2005) J Clin Oncol , vol.23 , pp. 8786-8793
    • Thienelt, C.D.1    Bunn, P.A.2    Hanna, N.3
  • 15
    • 37649022615 scopus 로고    scopus 로고
    • Randomized phase II study of gem-citabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer
    • Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gem-citabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007; 25:5777-5784
    • (2007) J Clin Oncol , vol.25 , pp. 5777-5784
    • Butts, C.A.1    Bodkin, D.2    Middleman, E.L.3
  • 16
    • 65349116059 scopus 로고    scopus 로고
    • Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomized phase III trial
    • Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 2009; 373:1525-1531
    • (2009) Lancet , vol.373 , pp. 1525-1531
    • Pirker, R.1    Pereira, J.R.2    Szczesna, A.3
  • 17
    • 62549097420 scopus 로고    scopus 로고
    • Overall survival (OS) results from the phase III trial BMS099: Cetuximab+taxane/carboplatin as 1st-line treatment for advanced NSCLC
    • Lynch TJ, Patel T, Dreisbach L, et al. Overall survival (OS) results from the phase III trial BMS099: cetuximab+taxane/carboplatin as 1st-line treatment for advanced NSCLC. J Thorac Oncol 2008; 3(suppl 4):s305.
    • (2008) J Thorac Oncol , vol.3 , Issue.SUPPL 4
    • Lynch, T.J.1    Patel, T.2    Dreisbach, L.3
  • 18
    • 49049089802 scopus 로고    scopus 로고
    • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    • Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3643-3651
    • (2008) J Clin Oncol , vol.26 , pp. 3643-3651
    • Scagliotti, G.V.1    Parikh, P.2    Von Pawel, J.3
  • 19
    • 70349092474 scopus 로고    scopus 로고
    • Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)
    • (abstract CRA8000)
    • Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27(suppl 18):407s (abstract CRA8000).
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL 18
    • Belani, C.P.1    Brodowicz, T.2    Ciuleanu, T.3
  • 20
    • 2942657615 scopus 로고    scopus 로고
    • Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
    • Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-2191
    • (2004) J Clin Oncol , vol.22 , pp. 2184-2191
    • Johnson, D.H.1    Fehrenbacher, L.2    Novotny, W.F.3
  • 21
    • 27544503230 scopus 로고    scopus 로고
    • Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomized, placebo-controlled multicentre study (Iressa Survival Evaluation in Lung Cancer)
    • Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-1537
    • (2005) Lancet , vol.366 , pp. 1527-1537
    • Thatcher, N.1    Chang, A.2    Parikh, P.3
  • 22
    • 33745001221 scopus 로고    scopus 로고
    • Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program
    • Thomas SK, Fossella FV, Liu D, et al. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 2006; 7:326-331
    • (2006) Clin Lung Cancer , vol.7 , pp. 326-331
    • Thomas, S.K.1    Fossella, F.V.2    Liu, D.3
  • 23
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957
    • (2009) N Engl J Med , vol.361 , pp. 947-957
    • Mok, T.S.1    Wu, Y.-L.2    Thongprasert, S.3
  • 24
    • 51349109631 scopus 로고    scopus 로고
    • FLEX: A randomized, multicenter, phase II study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
    • (abstract 3)
    • Pirker R, Szczesna A, von Pawel J, et al. FLEX: a randomized, multicenter, phase II study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26(suppl 15):6s (abstract 3).
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL 15
    • Pirker, R.1    Szczesna, A.2    Von Pawel, J.3
  • 25
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    • Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139
    • (2004) N Engl J Med , vol.350 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3
  • 26
    • 2342624080 scopus 로고    scopus 로고
    • EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
    • Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500
    • (2004) Science , vol.304 , pp. 1497-1500
    • Paez, J.G.1    Jänne, P.A.2    Lee, J.C.3
  • 27
    • 4444344330 scopus 로고    scopus 로고
    • EGF receptor gene mutations are common in lung cancer from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    • Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancer from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-13311
    • (2004) Proc Natl Acad Sci USA , vol.101 , pp. 13306-13311
    • Pao, W.1    Miller, V.2    Zakowski, M.3
  • 28
    • 57149089886 scopus 로고    scopus 로고
    • EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: A historical comparison of patients treated before and after gefitinib approval in Japan
    • Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 2008; 26:5589-5595
    • (2008) J Clin Oncol , vol.26 , pp. 5589-5595
    • Takano, T.1    Fukui, T.2    Ohe, Y.3
  • 29
    • 45149084723 scopus 로고    scopus 로고
    • First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    • Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26:2442-2449
    • (2008) J Clin Oncol , vol.26 , pp. 2442-2449
    • Sequist, L.V.1    Martins, R.G.2    Spigel, D.3
  • 30
    • 20244388126 scopus 로고    scopus 로고
    • Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
    • Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23:2513-2520
    • (2005) J Clin Oncol , vol.23 , pp. 2513-2520
    • Mitsudomi, T.1    Kosaka, T.2    Endoh, H.3
  • 31
    • 23844490782 scopus 로고    scopus 로고
    • Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinoma
    • Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinoma. Clin Cancer Res 2005; 11:5878-5885
    • (2005) Clin Cancer Res , vol.11 , pp. 5878-5885
    • Taron, M.1    Ichinose, Y.2    Rosell, R.3
  • 32
    • 85031335304 scopus 로고    scopus 로고
    • Biomarker analyses from an open-label study of erlotinib in advanced non-small-cell lung cancer (NSCLC)
    • (abstract 19012)
    • Van Zandwijk N, Su W, Rooneem R, et al. Biomarker analyses from an open-label study of erlotinib in advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 2008; 26(suppl 15):707s (abstract 19012).
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL 15
    • Van Zandwijk, N.1    Su, W.2    Rooneem, R.3
  • 33
    • 20244389188 scopus 로고    scopus 로고
    • Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
    • Han S-W, Kim T-Y, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23:2493-2501
    • (2005) J Clin Oncol , vol.23 , pp. 2493-2501
    • Han, S.-W.1    Kim, T.-Y.2    Hwang, P.G.3
  • 35
    • 10844231985 scopus 로고    scopus 로고
    • Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications
    • Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64:8919-8923
    • (2004) Cancer Res , vol.64 , pp. 8919-8923
    • Kosaka, T.1    Yatabe, Y.2    Endoh, H.3
  • 36
    • 28844449401 scopus 로고    scopus 로고
    • Epidermal growth factor receptor mutations and gene amplification non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials
    • Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23:8081-8092
    • (2005) J Clin Oncol , vol.23 , pp. 8081-8092
    • Bell, D.W.1    Lynch, T.J.2    Haserlat, S.M.3
  • 37
    • 24944497744 scopus 로고    scopus 로고
    • Mutations in the epidermal growth factor receptor in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
    • Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23:5900-5909
    • (2005) J Clin Oncol , vol.23 , pp. 5900-5909
    • Eberhard, D.A.1    Johnson, B.E.2    Amler, L.C.3
  • 38
    • 34248380395 scopus 로고    scopus 로고
    • Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy ± erlotinib (TALENT)
    • (abstract 7028)
    • Gatzemeier U, Heller A, Foernzler D, et al. Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy ± erlotinib (TALENT). J Clin Oncol 2005; 23(suppl 16):627s (abstract 7028).
    • (2005) J Clin Oncol , vol.23 , Issue.SUPPL 16
    • Gatzemeier, U.1    Heller, A.2    Foernzler, D.3
  • 39
    • 70349476965 scopus 로고    scopus 로고
    • Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC
    • (abstract 8020)
    • Brugger W, Triller N, Blasinska-Morawiec M, et al. Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC. J Clin Oncol 2009; 27(suppl 15):411s (abstract 8020).
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL 15
    • Brugger, W.1    Triller, N.2    Blasinska-Morawiec, M.3
  • 40
    • 76149126918 scopus 로고    scopus 로고
    • K-Ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: Retrospective analyses of the BMS099 trial
    • (abstract 8021)
    • Khambata-Ford S, Harbison CT, Woytowitz D, et al. K-Ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: retrospective analyses of the BMS099 trial. J Clin Oncol 2009; 27(suppl 15):412s (abstract 8021).
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL 15
    • Khambata-Ford, S.1    Harbison, C.T.2    Woytowitz, D.3
  • 41
    • 75749099198 scopus 로고    scopus 로고
    • Molecular and clinical biomarkers of cetuximab efficacy: Data from the phase III FLEX study in non-small cell lung cancer (NSCLC)
    • (abstract B2.3)
    • Gatzemeier U, Paz-Ares L, Pereira J, et al. Molecular and clinical biomarkers of cetuximab efficacy: data from the phase III FLEX study in non-small cell lung cancer (NSCLC). J Thor Oncol 2009; 4(9 suppl 1):s324; (abstract B2.3).
    • (2009) J Thor Oncol , vol.4 , Issue.9 SUPPL 1
    • Gatzemeier, U.1    Paz-Ares, L.2    Pereira, J.3
  • 42
    • 53949092103 scopus 로고    scopus 로고
    • Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST)
    • (abstract 8001)
    • Douillard J, Hirsh V, Mok TS, et al. Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). J Clin Oncol 2008; 26(suppl 15):424s (abstract 8001).
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL 15
    • Douillard, J.1    Hirsh, V.2    Mok, T.S.3
  • 43
    • 33750962024 scopus 로고    scopus 로고
    • Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
    • Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24:5034-5042
    • (2006) J Clin Oncol , vol.24 , pp. 5034-5042
    • Hirsch, F.R.1    Varella-Garcia, M.2    Bunn Jr., P.A.3
  • 44
    • 52049090365 scopus 로고    scopus 로고
    • Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study Br.21
    • Zhu C-Q, da Cuhna Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study Br.21. J Clin Oncol 2008; 26:4268-4275
    • (2008) J Clin Oncol , vol.26 , pp. 4268-4275
    • Zhu, C.-Q.1    Da Cuhna Santos, G.2    Ding, K.3
  • 45
    • 70349725169 scopus 로고    scopus 로고
    • S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study
    • (abstract 8015)
    • Gandara D, Kim E, Herbst R, et al. S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): a SWOG phase II study. J Clin Oncol 2009; 27(suppl 15):410s (abstract 8015).
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL 15
    • Gandara, D.1    Kim, E.2    Herbst, R.3
  • 46
    • 52049096854 scopus 로고    scopus 로고
    • Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): A randomized, phase II study
    • Crinò L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008; 26:4253-4260
    • (2008) J Clin Oncol , vol.26 , pp. 4253-4260
    • Crinò, L.1    Cappuzzo, F.2    Zatloukal, P.3
  • 47
    • 58149151261 scopus 로고    scopus 로고
    • Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer
    • Hirsch FR, Varella-Garcia M, Dziadziuszko R, et al. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res 2008; 14:6317-6323
    • (2008) Clin Cancer Res , vol.14 , pp. 6317-6323
    • Hirsch, F.R.1    Varella-Garcia, M.2    Dziadziuszko, R.3
  • 48
    • 49149127726 scopus 로고    scopus 로고
    • Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy
    • Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008; 26:3351-3357
    • (2008) J Clin Oncol , vol.26 , pp. 3351-3357
    • Hirsch, F.R.1    Herbst, R.S.2    Olsen, C.3
  • 49
    • 27244443759 scopus 로고    scopus 로고
    • Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study
    • Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005; 23:6838-6845
    • (2005) J Clin Oncol , vol.23 , pp. 6838-6845
    • Hirsch, F.R.1    Varella-Garcia, M.2    McCoy, J.3
  • 50
    • 27244451321 scopus 로고    scopus 로고
    • Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
    • Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23:6829-6837
    • (2005) J Clin Oncol , vol.23 , pp. 6829-6837
    • Takano, T.1    Ohe, Y.2    Sakamoto, H.3
  • 51
    • 41149097557 scopus 로고    scopus 로고
    • Molecular characteristics of bronchio-loalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib
    • Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchio-loalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008; 26:1472-1478
    • (2008) J Clin Oncol , vol.26 , pp. 1472-1478
    • Miller, V.A.1    Riely, G.J.2    Zakowski, M.F.3
  • 53
    • 34250161814 scopus 로고    scopus 로고
    • Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: The ONCOBELL trial
    • Cappuzzo F, Ligorio C, Jänne PA, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 2007; 25:2248-2255
    • (2007) J Clin Oncol , vol.25 , pp. 2248-2255
    • Cappuzzo, F.1    Ligorio, C.2    Jänne, P.A.3
  • 54
    • 33744832399 scopus 로고    scopus 로고
    • Epidermal growth factor receptor messenger RNA exprsession, gene dosage, and gefitinib sensitivity in non-small cell lung cancer
    • Dziadziuszko R, Witta SE, Cappuzzo F, et al. Epidermal growth factor receptor messenger RNA exprsession, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res 2006; 12:3078-3084
    • (2006) Clin Cancer Res , vol.12 , pp. 3078-3084
    • Dziadziuszko, R.1    Witta, S.E.2    Cappuzzo, F.3
  • 55
    • 52449101985 scopus 로고    scopus 로고
    • A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy
    • Felip E, Rojo F, Reck M, et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 2008; 14:3867-3874
    • (2008) Clin Cancer Res , vol.14 , pp. 3867-3874
    • Felip, E.1    Rojo, F.2    Reck, M.3
  • 56
    • 68949124435 scopus 로고    scopus 로고
    • Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study
    • (abstract 8007)
    • O'Byrne KJ, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the FLEX study. J Clin Oncol 2009; 27(suppl 15):408s (abstract 8007).
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL 15
    • O'Byrne, K.J.1    Bondarenko, I.2    Barrios, C.3
  • 57
    • 37649016023 scopus 로고    scopus 로고
    • A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): Final report of SWOG 0342
    • (abstract 7545)
    • Herbst RS, Chansky K, Kelly K, et al. A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): final report of SWOG 0342. J Clin Oncol 2007; 25(suppl 18):395s (abstract 7545).
    • (2007) J Clin Oncol , vol.25 , Issue.SUPPL 18
    • Herbst, R.S.1    Chansky, K.2    Kelly, K.3
  • 58
    • 0142119289 scopus 로고    scopus 로고
    • Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis
    • Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21:3798-3807
    • (2003) J Clin Oncol , vol.21 , pp. 3798-3807
    • Hirsch, F.R.1    Varella-Garcia, M.2    Bunn Jr., P.A.3
  • 59
    • 58549114891 scopus 로고    scopus 로고
    • Can epidermal growth factor receptor-fluorescent in situ hybridization predict clinical benefit from cetuximab treatment in patients with non-small-cell lung cancer?
    • Takano T, Ota S, Hori A, et al. Can epidermal growth factor receptor-fluorescent in situ hybridization predict clinical benefit from cetuximab treatment in patients with non-small-cell lung cancer? J Clin Oncol 2009; 27:464-465
    • (2009) J Clin Oncol , vol.27 , pp. 464-465
    • Takano, T.1    Ota, S.2    Hori, A.3
  • 60
    • 71649096662 scopus 로고    scopus 로고
    • Biomarker analysis from completely resected NSCLC patients enrolled in an adjuvant erlotinib clinical trial (RADIANT)
    • (abstract 7520)
    • Richardson F, Richardson K, Sennello G, et al. Biomarker analysis from completely resected NSCLC patients enrolled in an adjuvant erlotinib clinical trial (RADIANT). J Clin Oncol 2009; 27(suppl 15):387s (abstract 7520).
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL 15
    • Richardson, F.1    Richardson, K.2    Sennello, G.3
  • 61
    • 4644371906 scopus 로고    scopus 로고
    • Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy
    • (abstract 7013)
    • Bailey LR, Janas M, Schmidt K, et al. Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy. J Clin Oncol 2004; 22(suppl 14):618 (abstract 7013).
    • (2004) J Clin Oncol , vol.22 , Issue.SUPPL 14 , pp. 618
    • Bailey, L.R.1    Janas, M.2    Schmidt, K.3
  • 62
    • 22044453790 scopus 로고    scopus 로고
    • Erlotinib in lung cancer - Molecular and clinical predictors of outcome
    • Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353:133-144
    • (2005) N Engl J Med , vol.353 , pp. 133-144
    • Tsao, M.S.1    Sakurada, A.2    Cutz, J.C.3
  • 63
    • 5644296647 scopus 로고    scopus 로고
    • Geftinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: Tumor response is not clinically relevantly predictable form tumor EGFR membrane staining alone
    • [Abstract]
    • Bailey R, Kris M, Wolf M, et al. Geftinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable form tumor EGFR membrane staining alone. Lung Cancer 2003; 41:S71. [Abstract]
    • (2003) Lung Cancer , vol.41
    • Bailey, R.1    Kris, M.2    Wolf, M.3
  • 64
    • 77952486286 scopus 로고    scopus 로고
    • SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC)
    • (abstract 11076)
    • Franklin W, Gandara DR, Kim ES, et al. SWOG S0342 and S0536: expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27(suppl 15):576s (abstract 11076).
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL 15
    • Franklin, W.1    Gandara, D.R.2    Kim, E.S.3
  • 65
    • 77952467994 scopus 로고    scopus 로고
    • KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536
    • (abstract 8022)
    • Mack PC, Holland WS, Redman M, et al. KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. J Clin Oncol 2009; 27(suppl 15):412s (abstract 8022).
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL 15
    • MacK, P.C.1    Holland, W.S.2    Redman, M.3
  • 66
    • 65349189958 scopus 로고    scopus 로고
    • American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patient with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
    • Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patient with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27:2091-2096
    • (2009) J Clin Oncol , vol.27 , pp. 2091-2096
    • Allegra, C.J.1    Jessup, J.M.2    Somerfield, M.R.3
  • 67
    • 58549114891 scopus 로고    scopus 로고
    • Can epidermal growth factor receptor-fluorescent in situ hybridization predict clinical benefit from cetuximab treatment in patients with non-small-cell lung cancer?
    • Hirsch FR, Herbst RS, Olsen C, et al. Can epidermal growth factor receptor-fluorescent in situ hybridization predict clinical benefit from cetuximab treatment in patients with non-small-cell lung cancer? J Clin Oncol 2009; 27:464-465
    • (2009) J Clin Oncol , vol.27 , pp. 464-465
    • Hirsch, F.R.1    Herbst, R.S.2    Olsen, C.3
  • 69
    • 51649120733 scopus 로고    scopus 로고
    • KRAS status and efficacy in the firstline treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience
    • (abstract 2)
    • Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the firstline treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 2008; 26(suppl 15):5s (abstract 2).
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL 15
    • Van Cutsem, E.1    Lang, I.2    D'Haens, G.3
  • 70
    • 51649120733 scopus 로고    scopus 로고
    • KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience
    • (abstract 4000)
    • Bokemeyer C, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 2008; 26(suppl 15):178s (abstract 4000).
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL 15
    • Bokemeyer, C.1    Bondarenko, I.2    Hartmann, J.T.3
  • 71
    • 54949085398 scopus 로고    scopus 로고
    • K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    • Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-1765
    • (2008) N Engl J Med , vol.359 , pp. 1757-1765
    • Karapetis, C.S.1    Khambata-Ford, S.2    Jonker, D.J.3
  • 72
    • 69949111615 scopus 로고    scopus 로고
    • Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599
    • (abstract 8032)
    • Zhang W, Dahlberg SE, Yang D, et al. Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: subset pharmacogenetic analysis of ECOG 4599. J Clin Oncol 2009; 27(suppl 15):414s (abstract 8032).
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL 15
    • Zhang, W.1    Dahlberg, S.E.2    Yang, D.3
  • 73
    • 33750579074 scopus 로고    scopus 로고
    • RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer
    • Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006; 24:4731-4737
    • (2006) J Clin Oncol , vol.24 , pp. 4731-4737
    • Bepler, G.1    Kusmartseva, I.2    Sharma, S.3
  • 74
    • 33748435058 scopus 로고    scopus 로고
    • DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
    • Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-991
    • (2006) N Engl J Med , vol.355 , pp. 983-991
    • Olaussen, K.A.1    Dunant, A.2    Fouret, P.3
  • 75
    • 34447573875 scopus 로고    scopus 로고
    • Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer
    • Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007; 25:2747-2754
    • (2007) J Clin Oncol , vol.25 , pp. 2747-2754
    • Cobo, M.1    Isla, D.2    Massuti, B.3
  • 76
    • 0035988959 scopus 로고    scopus 로고
    • Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer
    • Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8:2286-2291
    • (2002) Clin Cancer Res , vol.8 , pp. 2286-2291
    • Lord, R.V.1    Brabender, J.2    Gandara, D.3
  • 77
    • 33845361135 scopus 로고    scopus 로고
    • ERCC1 and RRM1 gene expression but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
    • Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expression but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006; 17:1818-1825
    • (2006) Ann Oncol , vol.17 , pp. 1818-1825
    • Ceppi, P.1    Volante, M.2    Novello, S.3
  • 78
    • 33744486046 scopus 로고    scopus 로고
    • Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines
    • Kwon WS, Rha SY, Choi YH, et al. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics 2006; 16:429-438
    • (2006) Pharmacogenet Genomics , vol.16 , pp. 429-438
    • Kwon, W.S.1    Rha, S.Y.2    Choi, Y.H.3
  • 79
    • 2542530631 scopus 로고    scopus 로고
    • An increase in the expression of ribo-nucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines
    • Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribo-nucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004; 64:3761-3766
    • (2004) Cancer Res , vol.64 , pp. 3761-3766
    • Davidson, J.D.1    Ma, L.2    Flagella, M.3
  • 80
    • 33847645479 scopus 로고    scopus 로고
    • Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluoruracil/oxaliplatin chemotherapy in advanced gastric cancer
    • Kwon H-C, Roh MS, Oh SY, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluoruracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007; 18:504-509
    • (2007) Ann Oncol , vol.18 , pp. 504-509
    • Kwon, H.-C.1    Roh, M.S.2    Oh, S.Y.3
  • 81
    • 77952477678 scopus 로고    scopus 로고
    • Correlation of RRM1 promoter regions single nucleotide polymorphisms (SNPs) with response and outcome in breast cancer patients treated with gemcitabine-based chemotherapy
    • (abstract 14513)
    • Yeo W, Soong RC, Chuah BY, et al. Correlation of RRM1 promoter regions single nucleotide polymorphisms (SNPs) with response and outcome in breast cancer patients treated with gemcitabine-based chemotherapy. J Clin Oncol 2008; 26(suppl 15):629s (abstract 14513).
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL 15
    • Yeo, W.1    Soong, R.C.2    Chuah, B.Y.3
  • 82
    • 4444377694 scopus 로고    scopus 로고
    • Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the firstline treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC)
    • (abstract 7012)
    • Rosell R, Daniel C, Ramlau R, et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the firstline treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 2004; 22(suppl 14):618 (abstract 7012).
    • (2004) J Clin Oncol , vol.22 , Issue.SUPPL 14 , pp. 618
    • Rosell, R.1    Daniel, C.2    Ramlau, R.3
  • 84
    • 33749587054 scopus 로고    scopus 로고
    • Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase
    • Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107:1589-1596
    • (2006) Cancer , vol.107 , pp. 1589-1596
    • Ceppi, P.1    Volante, M.2    Saviozzi, S.3
  • 85
    • 3042756923 scopus 로고    scopus 로고
    • Thymidylate synthase and dihydropyrim-idine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluoruracil in patient with non-small-cell lung cancer
    • Shintani Y, Ohta M, Hirabayashi H, et al. Thymidylate synthase and dihydropyrim-idine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluoruracil in patient with non-small-cell lung cancer. Lung Cancer 2004; 45:189-196
    • (2004) Lung Cancer , vol.45 , pp. 189-196
    • Shintani, Y.1    Ohta, M.2    Hirabayashi, H.3
  • 86
    • 0032554076 scopus 로고    scopus 로고
    • Cloning and sequencing of human betaIII-tubulin cDNA: Induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents
    • Ranganathan S, Dexter DW, Benetatos CA, Hudes GR. Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. Biochim Biophys Acta 1998; 1395:237-245
    • (1998) Biochim Biophys Acta , vol.1395 , pp. 237-245
    • Ranganathan, S.1    Dexter, D.W.2    Benetatos, C.A.3    Hudes, G.R.4
  • 87
    • 0030931827 scopus 로고    scopus 로고
    • Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes
    • Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997; 100:1282-1293
    • (1997) J Clin Invest , vol.100 , pp. 1282-1293
    • Kavallaris, M.1    Kuo, D.Y.2    Burkhart, C.A.3
  • 88
    • 0033063875 scopus 로고    scopus 로고
    • Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations
    • Monzó M, Rosell R, Sánchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999; 17:1786-1793
    • (1999) J Clin Oncol , vol.17 , pp. 1786-1793
    • Monzó, M.1    Rosell, R.2    Sánchez, J.J.3
  • 89
    • 30344437279 scopus 로고    scopus 로고
    • Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel
    • DOI 10.1158/1535-7163.MCT-05-0244
    • Sève P, Mackey J, Isaac S, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005; 4:2001-2007 (Pubitemid 43056983)
    • (2005) Molecular Cancer Therapeutics , vol.4 , Issue.12 , pp. 2001-2007
    • Seve, P.1    Mackey, J.2    Isaac, S.3    Tredan, O.4    Souquet, P.-J.5    Perol, M.6    Lai, R.7    Voloch, A.8    Dumontet, C.9
  • 90
    • 14544302690 scopus 로고    scopus 로고
    • Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy
    • Dumontet C, Isaac S, Souquet PJ, et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005; 92:E25-30.
    • (2005) Bull Cancer , vol.92
    • Dumontet, C.1    Isaac, S.2    Souquet, P.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.